Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Real-World Uptake of Frontline Brentuximab Vedotin in Classical Hodgkin Lymphoma: A National Cancer Database Analysis

HL - 1598

Real-World Uptake of Frontline Brentuximab Vedotin in Classical Hodgkin Lymphoma: A National Cancer Database Analysis

Rita Ahmad

Poster Presenter: Rita Ahmad

Thumbnail for Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets =50Χ109/L at Initiation (TRIPAC)

MPN - 1200

Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets =50Χ109/L at Initiation (TRIPAC)

Faizan Sattar

Poster Presenter: Faizan Sattar

Previous 1...103 104 105 106 107 108 109...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Real-World Utilization and Survival Outcomes of Palliative Radiation Therapy in Patients With Multiple Myeloma Receiving BCMA-Targeted Therapies: A Propensity Score-Matched TriNetX Analysis

MM - 948

Real-World Utilization and Survival Outcomes of Palliative Radiation Therapy in Patients With Multiple Myeloma Receiving BCMA-Targeted Therapies: A Propensity Score-Matched TriNetX Analysis

Wei Ju Lin

Poster Presenter: Wei Ju Lin

Thumbnail for Redefining "Safe" Anthracycline Limits: A Restricted Cubic Spline Meta-Analysis of Continuous Cumulative Dosing and Non-Linear Cardiotoxicity in Hodgkin Lymphoma Survivors

HL - 1461

Redefining "Safe" Anthracycline Limits: A Restricted Cubic Spline Meta-Analysis of Continuous Cumulative Dosing and Non-Linear Cardiotoxicity in Hodgkin Lymphoma Survivors

Haroon Alamy

Poster Presenter: Haroon Alamy

Thumbnail for Redefining the Horizon: A Deep Survival Mixture Meta-Analysis Quantifying the Statistical Cure Fraction of Cellular Therapies in Relapsed Multiple Myeloma

MM - 1520

Redefining the Horizon: A Deep Survival Mixture Meta-Analysis Quantifying the Statistical Cure Fraction of Cellular Therapies in Relapsed Multiple Myeloma

Haroon Alamy

Poster Presenter: Haroon Alamy

Thumbnail for Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib ComparedWith Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-MatchedReal-World Analysis

CML - 1365

Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib ComparedWith Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-MatchedReal-World Analysis

Layal Sharrouf

Poster Presenter: Layal Sharrouf

$Thumbnail for Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity$

MM - 263

Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

$Thumbnail for Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies$

MM - 574

Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

Thumbnail for Reduction in Thyroid Volume in Patients With Chronic Myeloid Leukemia After Imatinib Treatment: A Prospective Cohort Study

CML - 029

Reduction in Thyroid Volume in Patients With Chronic Myeloid Leukemia After Imatinib Treatment: A Prospective Cohort Study

Ibrahim Ahmed

Poster Presenter: Ibrahim Ahmed

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors